9year low..., page-54

Markie- Thanks for the response.

I appreciate your opinion, even if i don't agree with all of it.

You do make some good points regarding the cash burn. The 5.3mil per quarter in "staff costs" is unacceptable, and not sustainable even after a full ramp up in the EU/ increases in yield. This number would need to be significantly reduced. Along with R&D.

However Cash burn has been high for years with this company, it's nothing new for the SP to factor in. Holders( yourself included) should of realized this years ago? How long have you followed this stock for?

Cash reserves at the moment are looking good historically speaking, and PXS is also closer than ever to FDA approval/ extended approval in the EU. Looking back at previous position's of this company relative to Market cap, there's no way it should be sitting in it's current state.( Under 100mil)

I agree the terms of the Novaquest funding won't be favorable for the company or for us shareholders. However cash is king in the short term, and a short term boost is what we need right now...